Combinations of Radiotherapy with Vaccination and Immune Checkpoint Inhibition Differently Affect Primary and Abscopal Tumor Growth and the Tumor Microenvironment.

abscopal effect high hydrostatic pressure immune checkpoint inhibition radiotherapy tumor microenvironment tumor-infiltrating immune cells vaccination

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
09 Feb 2021
Historique:
received: 26 01 2021
revised: 03 02 2021
accepted: 04 02 2021
entrez: 12 2 2021
pubmed: 13 2 2021
medline: 13 2 2021
Statut: epublish

Résumé

Radiotherapy (RT) is known to have immune-modulatory properties. We hypothesized that RT and inactivated whole tumor cell vaccines generated with high hydrostatic pressure (HHP) synergize to retard the tumor growth which can be additionally improved with anti-PD-1 treatment. In abscopal tumor models, we injected mice with B16-F10 melanoma or TS/A mammary tumors. To evaluate the efficiency of RT in combination with HHP vaccines, we locally irradiated only one tumor with 2 × 8 Gy or 3 × 8 Gy. HHP vaccines further retarded the growth of locally irradiated (2 × 8 Gy) tumors. However, HHP vaccination combined with RT failed to induce abscopal anti-tumor immune responses, namely those to non-irradiated tumors, and even partly abrogated those which were induced with RT plus anti-PD-1. In the latter group, the abscopal effects were accompanied by an elevated infiltration of CD8+ T cells, monocytes/macrophages, and dendritic cells. 3 × 8 Gy failed to induce abscopal effects in association with increased expression of immunosuppressive checkpoint molecules compared to 2 × 8 Gy. We conclude that HHP vaccines induce anti-tumor effects, but only if the tumor microenvironment was previously modulated by hypofractionated RT with not too many fractions, but failed to improve RT plus anti-PD-induced abscopal responses that are characterized by distinct immune alterations.

Identifiants

pubmed: 33572437
pii: cancers13040714
doi: 10.3390/cancers13040714
pmc: PMC7916259
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : German Research Fundation
ID : GRK1660
Organisme : German Federal Ministry of Education and Research
ID : 02NUK017G and 02NUK050E

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Cancers (Basel). 2020 Mar 18;12(3):
pubmed: 32197352
Cureus. 2019 Feb 20;11(2):e4103
pubmed: 31057997
Cell Death Dis. 2015 Jun 18;6:e1792
pubmed: 26086965
J Clin Invest. 2018 Apr 2;128(4):1338-1354
pubmed: 29480817
J Immunol Res. 2016;2016:6530410
pubmed: 27446967
Front Immunol. 2019 Feb 12;10:9
pubmed: 30809220
Immunity. 2018 Jul 17;49(1):178-193.e7
pubmed: 29958801
Lancet Oncol. 2015 Jul;16(7):795-803
pubmed: 26095785
J Immunother Cancer. 2015 Sep 15;3:43
pubmed: 26380088
J Zhejiang Univ Sci B. 2005 Sep;6(9):919-25
pubmed: 16130196
Front Oncol. 2019 Aug 28;9:805
pubmed: 31555582
Semin Cancer Biol. 2016 Jun;37-38:77-95
pubmed: 26873647
Immunol Rev. 2006 Oct;213:146-58
pubmed: 16972902
Nat Med. 2019 Aug;25(8):1251-1259
pubmed: 31359002
J Immunother Cancer. 2019 Jun 25;7(1):160
pubmed: 31238970
Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):63-73
pubmed: 29534901
Br J Radiol. 1953 May;26(305):234-41
pubmed: 13042090
J Clin Oncol. 2015 Jun 10;33(17):1889-94
pubmed: 25667295
Br J Radiol. 2016 Oct;89(1066):20160472
pubmed: 27556933
Br J Radiol. 2020 May 1;93(1109):20200042
pubmed: 32101479
Cell Mol Biol (Noisy-le-grand). 2004 Jun;50(4):459-67
pubmed: 15529755
Immunol Lett. 2017 Jul;187:27-34
pubmed: 28495513
Radiat Oncol. 2020 Nov 4;15(1):254
pubmed: 33148287
J Immunol. 2002 Oct 1;169(7):3760-70
pubmed: 12244170
Nat Rev Immunol. 2017 Feb;17(2):97-111
pubmed: 27748397
Cell Death Dis. 2018 May 29;9(6):648
pubmed: 29844348
Biochim Biophys Acta. 2002 Mar 25;1595(1-2):235-49
pubmed: 11983399
J Immunotoxicol. 2010 Jul-Sep;7(3):194-204
pubmed: 20205624
Cells. 2020 Feb 28;9(3):
pubmed: 32121071
Oncoimmunology. 2016 Dec 23;6(2):e1267095
pubmed: 28344877
PLoS One. 2011;6(7):e22560
pubmed: 21829468
Nat Commun. 2017 Jun 09;8:15618
pubmed: 28598415
Curr Med Chem. 2008;15(23):2329-36
pubmed: 18855663
Int J Oncol. 2019 Sep;55(3):684-696
pubmed: 31322183
Expert Rev Vaccines. 2014 Jun;13(6):721-35
pubmed: 24758597
Clin Cancer Res. 2009 Sep 1;15(17):5379-88
pubmed: 19706802
Cancer Cell. 2014 Nov 10;26(5):638-52
pubmed: 25446897
J Leukoc Biol. 1991 Apr;49(4):388-96
pubmed: 1900523
Nat Med. 2013 Apr;19(4):465-72
pubmed: 23455713
Int J Hyperthermia. 2016;32(1):23-30
pubmed: 26754406
J Exp Med. 2019 Oct 7;216(10):2394-2411
pubmed: 31375534
Sci Rep. 2017 Jul 7;7(1):4866
pubmed: 28687760
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):862-70
pubmed: 14967443
Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):212-224
pubmed: 32417411
J Immunol. 2013 Jan 15;190(2):613-20
pubmed: 23248259
Strahlenther Onkol. 2018 Jun;194(6):509-519
pubmed: 29500551
Ther Adv Vaccines Immunother. 2017 Dec;5(6):115-122
pubmed: 29998216
Clin Cancer Res. 2020 Feb 15;26(4):945-956
pubmed: 31694834
Nat Commun. 2019 Sep 2;10(1):3959
pubmed: 31477729
Proc Natl Acad Sci U S A. 2010 Oct 19;107(42):17992-7
pubmed: 20855610
Cancer Res. 2019 Jan 1;79(1):171-182
pubmed: 30413412
Clin Cancer Res. 2013 Aug 1;19(15):4046-57
pubmed: 23723299
Int J Mol Sci. 2018 Nov 13;19(11):
pubmed: 30428512
Cancer Res. 2014 Oct 1;74(19):5458-68
pubmed: 25274032
Int J Radiat Biol. 2020 Sep;96(9):1087-1103
pubmed: 32602416
Sci Rep. 2018 May 15;8(1):7565
pubmed: 29765096
Cancer Res. 2011 May 15;71(10):3437-41
pubmed: 21558390
Clin Cancer Res. 2020 Jun 15;26(12):2777-2782
pubmed: 32047000
Immunol Rev. 2017 Nov;280(1):231-248
pubmed: 29027224
Crit Rev Oncol Hematol. 2018 Mar;123:138-148
pubmed: 29482775
Curr Probl Cancer. 2016 Jan-Feb;40(1):25-37
pubmed: 26582738
Int J Cancer. 2014 Sep 1;135(5):1165-77
pubmed: 24500981
BMC Cancer. 2018 Mar 1;18(1):235
pubmed: 29490633
Cancer Discov. 2016 Jan;6(1):71-9
pubmed: 26493961
Oncoimmunology. 2017 Nov 27;7(3):e1395996
pubmed: 29399393
Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1306-10
pubmed: 22208977
Anticancer Res. 2017 Sep;37(9):4867-4871
pubmed: 28870907

Auteurs

Michael Rückert (M)

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.

Lisa Deloch (L)

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.

Benjamin Frey (B)

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.

Eberhard Schlücker (E)

Institute of Process Machinery and Systems Engineering, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91058 Erlangen, Germany.

Rainer Fietkau (R)

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.

Udo S Gaipl (US)

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.

Classifications MeSH